Nautilus
Delivering a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
Launch date
Employees
Market cap
$364m
Enterprise valuation
$229m (Public information from Sep 2024)
Share price
$3 NAUT
San Carlos California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | <1m | 10.6m | 34.2m |
% growth | - | - | - | - | - | 5108 % | 221 % |
EBITDA | (13.4m) | (47.7m) | (60.2m) | (70.4m) | (84.6m) | (97.8m) | (102m) |
% EBITDA margin | - | - | - | - | (41390 %) | (919 %) | (300 %) |
Profit | (15.6m) | (50.3m) | (57.9m) | (63.7m) | (82.9m) | (103m) | (109m) |
% profit margin | - | - | - | - | (40592 %) | (968 %) | (319 %) |
EV / revenue | - | - | - | - | 1339.7x | 25.0x | 6.2x |
EV / EBITDA | - | -6.2x | -0.7x | -2.8x | -3.2x | -2.7x | -2.0x |
R&D budget | 12.4m | 29.4m | 37.7m | 47.3m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $27.2m | Series A | |
* | $76.0m | Series B | |
$150m Valuation: $1.3b -97.0x EV/LTM EBITDA | SPAC IPO | ||
$200m Valuation: $1.3b -97.0x EV/LTM EBITDA | SPAC Private Placement | ||
N/A | N/A | IPO | |
Total Funding | $303m |